Brighton Jones LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

Brighton Jones LLC’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$987K	Sell	17,246 -10,533	-38%	-$577K	0.02%	514
2026 Q1	$1.57M	Buy	+27,779	New	+$1.62M	0.03%	330
2025 Q4	–	Sell	-26,000	Closed	-$1.41M	–	161
2025 Q3	$1.41M	Buy	26,000 +5,520	+27%	+$316K	0.03%	297
2025 Q2	$1.13M	Buy	+20,480	New	+$1.21M	0.03%	297

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Brighton Jones LLC's BMRN Position: Q2 2026 in Review

Brighton Jones LLC reduced its BioMarin Pharmaceuticals (BMRN) stake by 38% in Q2 2026, selling an estimated $577K and leaving 17,246 shares worth $987K. The position accounts for 0.02% of the portfolio, ranked #514.

Brighton Jones LLC first reported a position in BMRN in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.57M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Brighton Jones LLC held 17,246 shares of BioMarin Pharmaceuticals worth $987K as of Q2 2026.
Brighton Jones LLC sold 10,533 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $577K.
BioMarin Pharmaceuticals made up 0.02% of Brighton Jones LLC's portfolio in Q2 2026, its #514 holding.
Brighton Jones LLC first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
Brighton Jones LLC's BioMarin Pharmaceuticals position peaked at $1.57M in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Brighton Jones LLC's 13F filing for Q2 2026, filed 11 Aug 2026.